In the last trading session, 64588.0 Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) shares changed hands as the company’s beta touched 0.47. With the company’s per share price at $1.42 changed hands at -$0.02 or -1.39% during last session, the market valuation stood at $4.36M. SONN’s last price was a discount, traded about -1218.31% off its 52-week high of $18.72. When we look at Sonnet BioTherapeutics Holdings Inc’s average trading volume, we note the 10-day average is 0.36 million shares, with the 3-month average coming to 1.31 million.
Analysts gave the Sonnet BioTherapeutics Holdings Inc (SONN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SONN as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Sonnet BioTherapeutics Holdings Inc’s EPS for the current quarter is expected to be -11.12.
Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) trade information
Instantly SONN was in red as seen at the end of in last trading. With action -15.70%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -89.58%, with the 5-day performance at -15.70% in the red. However, in the 30-day time frame, Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) is -51.34% down. Looking at the short shares, we see there were 40115.0 shares sold at short interest cover period of 0.03 days.
Sonnet BioTherapeutics Holdings Inc (SONN) estimates and forecasts
Year-over-year growth is forecast to reach -100.00% down from the last financial year.
The company’s revenue for the corresponding quarters a year ago was 18.63k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -100.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 85.27%. The 2024 estimates are for Sonnet BioTherapeutics Holdings Inc earnings to increase by 69.87%.
SONN Dividends
Sonnet BioTherapeutics Holdings Inc is expected to release its next quarterly earnings report in January.
Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.38% of Sonnet BioTherapeutics Holdings Inc shares while 0.20% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 0.20%.
